Building capacity for the assessment of HIV drug resistance: Experiences from the pharmaccess African studies to evaluate resistance network

Raph L. Hamers, Elske Straatsma, Cissy Kityo, Carole L. Wallis, Wendy S. Stevens, Kim C.E. Sigaloff, Margaret Siwale, Francesca Conradie, Mariette E. Botes, Kishor Mandaliya, Maureen Wellington, Akin Osibogun, Michle Van Vugt, Tobias F.Rinke De Wit

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR), thus contributing to the goals of the World Health Organization Global HIV Drug Resistance Network. PASER disseminates information to medical professionals and policy makers and conducts observational research related to HIVDR. The sustainability of the network is challenged by funding limitations, constraints in human resources, a vulnerable general health infrastructure, and high cost and complexity of molecular diagnostic testing. This report highlights experiences and challenges in the PASER network from 2006 to 2010.

Original languageEnglish
JournalClinical Infectious Diseases
Volume54
Issue numberSUPPL. 4
DOIs
Publication statusPublished - 15 May 2012

Cite this

Hamers, Raph L. ; Straatsma, Elske ; Kityo, Cissy ; Wallis, Carole L. ; Stevens, Wendy S. ; Sigaloff, Kim C.E. ; Siwale, Margaret ; Conradie, Francesca ; Botes, Mariette E. ; Mandaliya, Kishor ; Wellington, Maureen ; Osibogun, Akin ; Van Vugt, Michle ; De Wit, Tobias F.Rinke. / Building capacity for the assessment of HIV drug resistance : Experiences from the pharmaccess African studies to evaluate resistance network. In: Clinical Infectious Diseases. 2012 ; Vol. 54, No. SUPPL. 4.
@article{da677a58a98d4598a970311843979329,
title = "Building capacity for the assessment of HIV drug resistance: Experiences from the pharmaccess African studies to evaluate resistance network",
abstract = "The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR), thus contributing to the goals of the World Health Organization Global HIV Drug Resistance Network. PASER disseminates information to medical professionals and policy makers and conducts observational research related to HIVDR. The sustainability of the network is challenged by funding limitations, constraints in human resources, a vulnerable general health infrastructure, and high cost and complexity of molecular diagnostic testing. This report highlights experiences and challenges in the PASER network from 2006 to 2010.",
author = "Hamers, {Raph L.} and Elske Straatsma and Cissy Kityo and Wallis, {Carole L.} and Stevens, {Wendy S.} and Sigaloff, {Kim C.E.} and Margaret Siwale and Francesca Conradie and Botes, {Mariette E.} and Kishor Mandaliya and Maureen Wellington and Akin Osibogun and {Van Vugt}, Michle and {De Wit}, {Tobias F.Rinke}",
year = "2012",
month = "5",
day = "15",
doi = "10.1093/cid/cir995",
language = "English",
volume = "54",
journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",
issn = "1058-4838",
number = "SUPPL. 4",

}

Hamers, RL, Straatsma, E, Kityo, C, Wallis, CL, Stevens, WS, Sigaloff, KCE, Siwale, M, Conradie, F, Botes, ME, Mandaliya, K, Wellington, M, Osibogun, A, Van Vugt, M & De Wit, TFR 2012, 'Building capacity for the assessment of HIV drug resistance: Experiences from the pharmaccess African studies to evaluate resistance network' Clinical Infectious Diseases, vol. 54, no. SUPPL. 4. https://doi.org/10.1093/cid/cir995

Building capacity for the assessment of HIV drug resistance : Experiences from the pharmaccess African studies to evaluate resistance network. / Hamers, Raph L.; Straatsma, Elske; Kityo, Cissy; Wallis, Carole L.; Stevens, Wendy S.; Sigaloff, Kim C.E.; Siwale, Margaret; Conradie, Francesca; Botes, Mariette E.; Mandaliya, Kishor; Wellington, Maureen; Osibogun, Akin; Van Vugt, Michle; De Wit, Tobias F.Rinke.

In: Clinical Infectious Diseases, Vol. 54, No. SUPPL. 4, 15.05.2012.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Building capacity for the assessment of HIV drug resistance

T2 - Experiences from the pharmaccess African studies to evaluate resistance network

AU - Hamers, Raph L.

AU - Straatsma, Elske

AU - Kityo, Cissy

AU - Wallis, Carole L.

AU - Stevens, Wendy S.

AU - Sigaloff, Kim C.E.

AU - Siwale, Margaret

AU - Conradie, Francesca

AU - Botes, Mariette E.

AU - Mandaliya, Kishor

AU - Wellington, Maureen

AU - Osibogun, Akin

AU - Van Vugt, Michle

AU - De Wit, Tobias F.Rinke

PY - 2012/5/15

Y1 - 2012/5/15

N2 - The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR), thus contributing to the goals of the World Health Organization Global HIV Drug Resistance Network. PASER disseminates information to medical professionals and policy makers and conducts observational research related to HIVDR. The sustainability of the network is challenged by funding limitations, constraints in human resources, a vulnerable general health infrastructure, and high cost and complexity of molecular diagnostic testing. This report highlights experiences and challenges in the PASER network from 2006 to 2010.

AB - The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR), thus contributing to the goals of the World Health Organization Global HIV Drug Resistance Network. PASER disseminates information to medical professionals and policy makers and conducts observational research related to HIVDR. The sustainability of the network is challenged by funding limitations, constraints in human resources, a vulnerable general health infrastructure, and high cost and complexity of molecular diagnostic testing. This report highlights experiences and challenges in the PASER network from 2006 to 2010.

UR - http://www.scopus.com/inward/record.url?scp=84860360727&partnerID=8YFLogxK

U2 - 10.1093/cid/cir995

DO - 10.1093/cid/cir995

M3 - Article

VL - 54

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

SN - 1058-4838

IS - SUPPL. 4

ER -